SAN DIEGO, CA--(Marketwire - May 31, 2012) - Quidel Corporation (NASDAQ: [ QDEL ]), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the following upcoming conferences:

• The Goldman Sachs 33^rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California on Tuesday, June 5, 2012 at 3:20 p.m. Pacific Time.
  
  
• The William Blair 32^nd Annual Growth Stock Conference at the Four Seasons hotel in Chicago, Illinois on Tuesday, June 12, 2012 at 7:30 a.m. Central Time.
  
  

Douglas Bryant, president and chief executive officer, will present on the specified days with a question and answer session scheduled immediately following the presentations. During the presentations, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.

A live webcast and audio archive of the presentations will be available via the Investor Relations section of the company's Web site at [ www.quidel.com ]. Participants should allow approximately five to ten minutes prior to each presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of each webcast will also be available on the company's Web site for 14 days.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain™ leading brand names, as well as under the new Sofia® brand, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, [ influenza ], [ respiratory syncytial virus ], Strep A, herpes, pregnancy, [ thyroid disease ] and [ fecal occult blood ]. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit [ www.quidel.com ] and Diagnostic Hybrids at [ www.dhiusa.com ].